JP6676062B2 - 認知低下を処置するための方法 - Google Patents

認知低下を処置するための方法 Download PDF

Info

Publication number
JP6676062B2
JP6676062B2 JP2017542498A JP2017542498A JP6676062B2 JP 6676062 B2 JP6676062 B2 JP 6676062B2 JP 2017542498 A JP2017542498 A JP 2017542498A JP 2017542498 A JP2017542498 A JP 2017542498A JP 6676062 B2 JP6676062 B2 JP 6676062B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
thc
composition according
patient
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017542498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533276A5 (https=
JP2017533276A (ja
Inventor
ヨセフ サーン
ヨセフ サーン
Original Assignee
ラモト アト テルーアビブ ユニバーシティー リミテッド
ラモト アト テルーアビブ ユニバーシティー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラモト アト テルーアビブ ユニバーシティー リミテッド, ラモト アト テルーアビブ ユニバーシティー リミテッド filed Critical ラモト アト テルーアビブ ユニバーシティー リミテッド
Publication of JP2017533276A publication Critical patent/JP2017533276A/ja
Publication of JP2017533276A5 publication Critical patent/JP2017533276A5/ja
Application granted granted Critical
Publication of JP6676062B2 publication Critical patent/JP6676062B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017542498A 2014-11-03 2015-11-02 認知低下を処置するための方法 Expired - Fee Related JP6676062B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462074134P 2014-11-03 2014-11-03
US62/074,134 2014-11-03
PCT/IB2015/058453 WO2016071819A1 (en) 2014-11-03 2015-11-02 Methods for treatment of cognitive decline

Publications (3)

Publication Number Publication Date
JP2017533276A JP2017533276A (ja) 2017-11-09
JP2017533276A5 JP2017533276A5 (https=) 2018-10-25
JP6676062B2 true JP6676062B2 (ja) 2020-04-08

Family

ID=55908668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017542498A Expired - Fee Related JP6676062B2 (ja) 2014-11-03 2015-11-02 認知低下を処置するための方法

Country Status (7)

Country Link
US (1) US10660872B2 (https=)
EP (1) EP3215148B1 (https=)
JP (1) JP6676062B2 (https=)
CN (1) CN106999467A (https=)
AU (2) AU2015341458B2 (https=)
CA (1) CA2966710A1 (https=)
WO (1) WO2016071819A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033493B2 (en) 2013-12-02 2021-06-15 Intelgenx Corp. Film dosage form with extended release mucoadhesive particles
US11065225B1 (en) * 2015-07-30 2021-07-20 University Of South Florida Ultra-low dose THC as a potential therapeutic and prophylactic agent for Alzheimer's disease
US11446276B2 (en) 2015-07-30 2022-09-20 University Of South Florida Extreme low dose THC as a therapeutic and prophylactic agent for Alzheimer's disease
GB2549277B (en) * 2016-04-11 2021-02-17 Gw Res Ltd Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder
BR112020019768A2 (pt) 2018-03-30 2021-01-26 India Globalization Capital, Inc. método e composição para o tratamento de distúrbios do sistema nervoso central (snc)
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
US11602504B2 (en) 2018-11-05 2023-03-14 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US12303501B2 (en) 2018-11-05 2025-05-20 Intelgenx Corp. Lipophilic active oral film formulation and method of making the same
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804592A (en) * 1997-05-30 1998-09-08 Unimed Pharmaceuticals, Inc. Method for improving disturbed behavior and elevating mood in humans
US6509005B1 (en) 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
US7648696B2 (en) 1999-08-20 2010-01-19 Unimed Pharmaceuticals, Llc Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
US8039509B2 (en) 2006-11-10 2011-10-18 Johnson Matthey Public Limited Company Composition comprising (−)-Δ9-trans-tetrahydrocannabinol
EP2341903A1 (en) * 2008-07-31 2011-07-13 Bionorica Research GmbH Cannabinoids for use in treating or preventing cognitive impairment and dementia
WO2012068516A2 (en) 2010-11-18 2012-05-24 Pier Pharmaceuticals Low dose cannabinoid medicaments
GB2524469A (en) 2014-02-14 2015-09-30 Kind Consumer Ltd A cannabinoid inhaler and composition therefor

Also Published As

Publication number Publication date
CN106999467A (zh) 2017-08-01
WO2016071819A1 (en) 2016-05-12
US20170333387A1 (en) 2017-11-23
AU2015341458B2 (en) 2020-08-13
EP3215148A4 (en) 2018-06-13
EP3215148A1 (en) 2017-09-13
AU2020267285A1 (en) 2020-12-10
EP3215148B1 (en) 2022-04-13
JP2017533276A (ja) 2017-11-09
CA2966710A1 (en) 2016-05-12
US10660872B2 (en) 2020-05-26
AU2015341458A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
JP6676062B2 (ja) 認知低下を処置するための方法
EP2037902B1 (en) Cannabinoids for use in the treatment of neuropathic pain
JP2014074032A (ja) 嗜癖および鬱病を含むｍｇｌｕレセプターに関連する疾患を処置するためのｍｇｌｕレセプターアンタゴニスト
Havale et al. Comparative evaluation of pain perception following topical application of clove oil, betel leaf extract, lignocaine gel, and ice prior to intraoral injection in children aged 6–10 years: a randomized control study
KR101867633B1 (ko) 정신분열증을 치료하기 위한 시클릭 아미드 유도체의 사용 방법
JP2024507492A (ja) 精神療法を補助するためのメスカリン及びメスカリン類似体（スカリン）の効果
CN121443298A (zh) 用于治疗持续性脑震荡后症状的苯加兰他敏
CN104906501B (zh) 治疗银屑病的中药组分组合物
CN105726557B (zh) 异长春花苷内酰胺在制备治疗肠应激综合征的药物中的应用
Hinsie The treatment of schizophrenia: A survey of the literature
PFEFFERBAUM et al. Narcolepsy, paranoid psychosis, and tardive dyskinesia: a pharmacological dilemma
JP7579027B2 (ja) セスキテルペンラクトン系化合物の視神経炎治療薬の製造における使用
RU2468813C1 (ru) Средство для профилактики или лечения острых и хронических нарушений мозгового кровообращения, применение и способ лечения
Miculas et al. Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions. Cells 2023, 12, 131
Kale Pharmacology & Toxicology
CN107998126A (zh) 青蒿素的应用
JP6738797B2 (ja) レット症候群治療薬
WO2026052068A1 (zh) 药物组合物的用途
WO2021063387A1 (zh) 伊马替尼及其衍生物的组合物在制备预防、治疗及防治成瘾复吸药物中的应用
TWI599371B (zh) 醫藥組合物用於製備治療檳榔使用失調之藥物上的用途
CN102600154B (zh) 7-氯代硫犬尿酸在制备预防和/或治疗单相抑郁症的药物中的用途
WO2018029685A1 (en) Compositions and methods for treating a fear memory
WO1998026778A1 (en) Remedies/preventives for abnormal motions accompanying disorders in extrapyramidal system

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190904

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190905

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200311

R150 Certificate of patent or registration of utility model

Ref document number: 6676062

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees